Drug intelligence / Profile preview

EYS611

Development stage: Phase 2
Lead developer: PulseSight Therapeutics
Modality: Gene Therapies
Administration: Intramuscular, Intraocular

Overview

EYS611 (also known as PST-611) is a non-viral gene therapy developed for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) and retinitis pigmentosa. The therapy utilizes a proprietary electrotransfection system to deliver DNA plasmids into the ciliary muscle of the eye. This approach turns the ciliary muscle into a "biofactory" for the sustained production and secretion of human transferrin into the vitreous. Transferrin acts as a potent iron chelator, reducing iron-mediated oxidative stress and protecting retinal cells from degeneration. Originally developed by Eyevensys, the program was transitioned to PulseSight Therapeutics in 2024.

Other names: EYS611EYS-611EYS 611PST 611PST611PST-611

Beyond the preview

Go deeper on EYS611.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EYS611.

Explore the full profile